Cambium Bio Limited(CMB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

CMB.AU Cambium Bio Limited

Not Yet Opened 12-12 16:12:00 AEDT

0.48

+0.01

+1.05%

High0.48	Low0.48	Vol4.14K
Open0.48	D1 Closing0.48	Amplitude1.05%
Mkt Cap11.02M	Tradable Cap2.06M	Total Shares22.97M
T/O1.99K	T/O Rate0.10%	Tradable Shares4.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.48,"timestamp":1765516320000,"preClose":0.475,"halted":0,"volume":4139,"delay":0,"nameEN":"Cambium Bio Limited","floatShares":4291164,"shares":22968281,"eps":-0.0015,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"12-12 16:12:00 AEDT","open":0.475,"high":0.48,"low":0.475,"amount":1986,"amplitude":0.010526,"askPrice":0.585,"askSize":965,"bidPrice":0.48,"bidSize":3621,"shortable":3,"etf":0,"ttmEps":-0.0015,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765753200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.475,"openAndCloseTimeList":[[1765494000000,1765515600000]],"volumeRatio":3.505844960981869,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CMB.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2577153495","title":"Cambium Bio Ltd-Change of Directors Interest Notice - TW","url":"https://stock-news.laohu8.com/highlight/detail?id=2577153495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577153495?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:18","pubTimestamp":1761254302,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE5V61DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2577534952","title":"Cambium Bio Ltd-Change of Directors Interest Notice - Ew","url":"https://stock-news.laohu8.com/highlight/detail?id=2577534952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577534952?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:18","pubTimestamp":1761254292,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE13QGTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571434689","title":"BRIEF-Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2571434689","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571434689?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:25","pubTimestamp":1759227942,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate OcularSept 30 (Reuters) - Cambium Bio Ltd CMB.AX:SIGNS MOU WITH LOCUS CELL FOR MANUFACTURING OF ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2571394085","title":"Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2571394085","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571394085?lang=en_us&edition=fundamental","pubTime":"2025-09-30 12:17","pubTimestamp":1759205825,"startTime":"0","endTime":"0","summary":"Cambium Bio  executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571391933","title":"Cambium Bio - Signs Mou With Locus Cell for Manufacturing of Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2571391933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571391933?lang=en_us&edition=fundamental","pubTime":"2025-09-30 11:33","pubTimestamp":1759203188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571361332","title":"Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2571361332","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571361332?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:00","pubTimestamp":1759186800,"startTime":"0","endTime":"0","summary":"TAIPEI, Sept. 30, 2025 /PRNewswire/ -- Locus Cell , a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding  with Australia-based Cambium Bio . Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing  of Elate Ocular -related. Elate Ocular, a Phase III dry eye disease therapy currently under clinical trials in Taiwan, the U.S., and Australia. The technology originates from Cambium's parent company,Zheng Yang Biomedical Technology Co., Ltd.Locus Cell’s Zhubei Smart GMP Facility Secures Its First International Phase III CDMO Manufacturing MOU. From left: Karolis Rosickas, CEO of Cambium Bio; Yu-Hung Tseng, Chairman of Zheng Yang Biomedical Technology Co., Ltd.; and Jiunn-Rong Chiou, Chairman of Locus Cell.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2783933/Locus_Cell_s_Zhubei_Smart_GMP_Facility_Secures_Its_First_International_Phase_III_CDMO_Manufacturing.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2783933/Locus_Cell_s_Zhubei_Smart_GMP_Facility_Secures_Its_First_International_Phase_III_CDMO_Manufacturing.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/locus-cells-zhubei-smart-gmp-facility-secures-first-international-phase-iii-cdmo-manufacturing-mou-with-cambium-bio-302569079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","III","BK4139","BK4134","CMB.AU","CDMO"],"gpt_icon":0},{"id":"2565469536","title":"Cambium Bio Forms Partnership With French Pharmaceutical Firm; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565469536","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565469536?lang=en_us&edition=fundamental","pubTime":"2025-09-05 12:28","pubTimestamp":1757046499,"startTime":"0","endTime":"0","summary":"Cambium Bio  entered into a memorandum of understanding with Benta, a French pharmaceutical company, to establish a strategic partnership to develop and commercialize Elate Ocular for dry eye disease in Europe and the Middle East, according to a Friday Australian bourse filing.The company said the partnership will provide access to major European and Middle Eastern markets. Under the deal, Benta will facilitate exchanges with regulators in France and Europe, the Middle East, and Africa.The company's shares rose past 4% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2565533562","title":"BUZZ-Australia's Cambium Bio advances on signing MoU for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2565533562","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565533562?lang=en_us&edition=fundamental","pubTime":"2025-09-05 11:09","pubTimestamp":1757041795,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cambium Bio advances on signing MoU for Elate Ocular** Shares of Australia's Cambium Bio CMB.AX rise as much as 15.8% to A$0.55** Stock has gained 5.3% so far in the week, on track to record its second consecutive week of gains, if the trend holds** Regenerative medicine firm signs memorandum of understanding  with French pharma company Benta SAS** MoU to establish a strategic partnership for the development and commercialisation of Elate Ocular  for dry eye disease in Europe and the Middle East** Stock has risen 23.8% this year, as of 0304 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL4N3US077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2565874155","title":"Cambium Bio Ltd - Signs Mou With Benta Sas for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2565874155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565874155?lang=en_us&edition=fundamental","pubTime":"2025-09-05 09:37","pubTimestamp":1757036279,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nFWN3UR120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2564876311","title":"Cambium Bio Signs Licensing Deal for Fibrin Biologic in Dental Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2564876311","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564876311?lang=en_us&edition=fundamental","pubTime":"2025-09-02 14:36","pubTimestamp":1756794995,"startTime":"0","endTime":"0","summary":"Cambium Bio  has entered into a term sheet with Keke Medtech, granting exclusive worldwide rights to develop and commercialize the company's proprietary human platelet lysate-derived fibrin biologic product for dental and oral wound healing applications, according to a Tuesday Australian bourse filing.The deal includes an upfront payment of $250,000, of which $25,000 has already been received.The deal also includes development milestones of up to $1.75 million and 10% royalties on the first $10 million and 13% thereafter.The company will also receive a 20% share of non-royalty sublicense revenues.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2564225388","title":"Cambium Bio - Signs $2.0M Licensing Deal for Fibrin Biologic in Dental Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2564225388","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564225388?lang=en_us&edition=fundamental","pubTime":"2025-09-02 11:08","pubTimestamp":1756782486,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nFWN3UO0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2555939700","title":"BRIEF-Cambium Bio To Raise A$2.12 Million Through Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2555939700","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555939700?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:45","pubTimestamp":1753839911,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio To Raise A$2.12 Million Through PlacementJuly 30 (Reuters) - Cambium Bio Ltd CMB.AX:TO RAISE A$2.12 MILLION THROUGH PLACEMENT AT A$0.4637 PER SHAREFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TQ1HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2555098597","title":"Cambium Bio Ltd -  to Raise a$2.12 Mln Through Placement at a$0.4637 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2555098597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555098597?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:15","pubTimestamp":1753838132,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TQ1HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2555983270","title":"Cambium Bio Ltd-Proposed Issue of Securities - Cmb","url":"https://stock-news.laohu8.com/highlight/detail?id=2555983270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555983270?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:14","pubTimestamp":1753838096,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUEBZ7LX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2551152793","title":"China’s 2025H1 GDP Growth Beats Target — But Weak Domestic Demand Could Push CPI Into Deflation in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2551152793","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551152793?lang=en_us&edition=fundamental","pubTime":"2025-07-15 16:33","pubTimestamp":1752568411,"startTime":"0","endTime":"0","summary":"TradingKey - Driven by proactive macroeconomic policies, China’s Q2 GDP grew 5.2% year-over-year, slightly below Q1’s 5.4% but still above market expectations of 5.1%. For the first half of 2025, GDP expanded 5.3%, reaching a total value of ¥66.05 trillion. Despite Trump’s tariff war and global ","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20231130/ad307b1b3bd32a0f9f82b14e73cf5639.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20231130/ad307b1b3bd32a0f9f82b14e73cf5639.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/economic-indicator/250890177-china-economy-gdp-2025-export-consumer-deflation-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2550053106","title":"BUZZ-Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2550053106","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550053106?lang=en_us&edition=fundamental","pubTime":"2025-07-11 09:48","pubTimestamp":1752198531,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cambium Bio rises on a US FDA clearance for its dry eye treatment drug** Shares of Cambium Bio CMB.AX up as much as 30.2% to A$0.28, hitting highest level since April 24** Regenerative medicine maker says it cleared US FDA's regulatory requirements to initiate patient dosing in its Phase 3 clinical trials of Elate Ocular which can be used to treat dry eye disease** About 93,600 shares change hands, 18x the 30-day average ** Stock down 30% YTD, at current levels  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nL6N3T801W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2550722366","title":"BRIEF-Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2550722366","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550722366?lang=en_us&edition=fundamental","pubTime":"2025-07-11 08:05","pubTimestamp":1752192343,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Clears US FDA Regulatory Hurdles To Commence Phase 3 Dosing For Elate OcularJuly 11 (Reuters) - Cambium Bio Ltd CMB.AX:CLEARS US FDA REGULATORY HURDLES TO COMMENCE PHASE 3 DOSING FOR ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nFWN3T70O5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2550674089","title":"Cambium Bio Clears FDA Regulatory Hurdles-CMB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550674089","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550674089?lang=en_us&edition=fundamental","pubTime":"2025-07-11 07:10","pubTimestamp":1752189018,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASXbY1k96","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX2vXy3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2547424052","title":"Cambium Bio Secures US, Australia Ethical Approval for Phase Three Eye Disease Treatment Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2547424052","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547424052?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:19","pubTimestamp":1751267960,"startTime":"0","endTime":"0","summary":"Cambium Bio  secured ethics approval to begin its registration-enabling phase three clinical trials of Elate Ocular treatment candidate for the treatment of moderate to severe dry eye disease in both Australia and the US, according to a Monday Australian bourse filing.The ethics approval in Australia was granted by Bellberry Human Research Ethics Committee on June 26, while the approval in the US was granted by Advarra Institutional Review Board on May 9.The first patient dosing is anticipated in October, and it will randomize around 800 patients globally. The co-primary endpoints include improvement in total corneal fluorescein staining and eye discomfort VAS score, relating to dry eye disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XKO.AU","BK7067","XJO.AU","CMB.AU"],"gpt_icon":0},{"id":"2547803325","title":"Cambium Bio Receives Ethics Approvals-CMB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547803325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547803325?lang=en_us&edition=fundamental","pubTime":"2025-06-30 07:23","pubTimestamp":1751239387,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250629:nASXcL5CZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250629:nASXbrZS2p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0588},{"period":"3month","weight":-0.0588},{"period":"6month","weight":1.087},{"period":"1year","weight":-0.1111},{"period":"ytd","weight":0.2}],"compareEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":-0.0179},{"period":"3month","weight":0.0357},{"period":"6month","weight":0.0639},{"period":"1year","weight":0.2156},{"period":"ytd","weight":0.2302}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.137653},{"month":2,"riseRate":0.416667,"avgChangeRate":0.058201},{"month":3,"riseRate":0.416667,"avgChangeRate":0.013412},{"month":4,"riseRate":0.25,"avgChangeRate":-0.092826},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.056795},{"month":6,"riseRate":0.583333,"avgChangeRate":6.766948},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.015463},{"month":8,"riseRate":0.583333,"avgChangeRate":0.045234},{"month":9,"riseRate":0.230769,"avgChangeRate":-0.091648},{"month":10,"riseRate":0.538462,"avgChangeRate":0.128155},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.048017},{"month":12,"riseRate":0.166667,"avgChangeRate":0.060192}],"exchange":"ASX","name":"Cambium Bio Limited","nameEN":"Cambium Bio Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cambium Bio Limited(CMB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cambium Bio Limited(CMB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cambium Bio Limited,CMB.AU,Cambium Bio Limited股票,Cambium Bio Limited股票老虎,Cambium Bio Limited股票老虎国际,Cambium Bio Limited行情,Cambium Bio Limited股票行情,Cambium Bio Limited股价,Cambium Bio Limited股市,Cambium Bio Limited股票价格,Cambium Bio Limited股票交易,Cambium Bio Limited股票购买,Cambium Bio Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cambium Bio Limited(CMB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cambium Bio Limited(CMB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}